We encourage you to evaluate us alongside other options using the checklist above
Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management
"It's like a great pizza dip," he says
Poor diet, chronic stress, UV exposure, and environmental pollution are all contributors to such a condition
What This Means for Women in Midlife If you're considering a GLP-1 medication for weight management, the question isn't just "which medication?" it's "what else is going on hormonally?" For women in perimenopause or postmenopause, addressing estrogen deficiency may: Enhance the weight loss response to GLP-1 medications [1] Improve the metabolic benefits including better insulin sensitivity and reduced visceral fat [7, 8] Address symptoms like sleep disruption, hot flashes, and mood changes that can undermine weight loss efforts [10] Support long-term cardiovascular health during a period of accelerated risk [9] This is why a comprehensive approach one that evaluates both your metabolic health and your hormonal status matters so much more than choosing a single medication in isolation
